查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
抗生素抗藥性診斷市場:病原體，各技術，各地區的策略和趨勢 -附執行顧問指南(2025年～2029年)
市場調查報告書
商品編碼
1723117

抗生素抗藥性診斷市場:病原體，各技術，各地區的策略和趨勢 -附執行顧問指南(2025年～2029年)

Antimicrobial Resistance Diagnostic Markets, Strategies and Trends By Pathogen, By Technology, and By Region with Executive and Consultant Guides. 2025 To 2029
出版日期: | 出版商: Howe Sound Research | 英文 391 Pages | 商品交期: 最快1-2個工作天內

價格

報告概述

為了減輕抗菌素抗藥性所帶來的威脅，診斷技術正佔據主導地位。這些技術能否在新型抗生素出現前解決問題？為了抓住這個不斷成長的市場，人們正在開發超越基因定序的新型診斷技術。我們著眼於技術格局，幫助您了解診斷病原體和感染的不同方法。我們已經識別了該領域六種主要病原體的機會並制定了市場預測。我們分析了30家活躍於該領域的大型和小型企業。

利用最新數據進行投資決策與估價。

按本報告提供全球抗生素抗藥性診斷市場相關調查，提供市場概要，以及病原體，各技術，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場指南

第2章 簡介和市場定義

  • 抗生素抗藥性的威脅和機會
  • 機會定義
  • 方法與資訊來源
  • 觀點:醫療保健和IVD產業
  • 診斷費

第3章 動態的市場概要

  • 市場進入組織
    • 學術研究機關
    • 診斷測試開發商
    • 測量設備供應商
    • 藥品·試劑廠商
    • 病理供應商
    • 獨立型臨床檢驗室
    • 公共的國立/地區研究所
    • 醫院檢驗室
    • 臨床檢驗室
    • 審核機關
    • 認證機關
  • 關於抗生素抗藥性理解
  • 新抗生素與科技的改變之路
  • AMR的診斷的重要角色

第4章 AMR的市場機會

  • AMR的主要大規模市場機會
  • 診斷技術開發機會

第5章 抗生素抗性診斷最近的趨勢

第6章 主要AMR診斷企業

  • 1928 Diagnostics
  • Abbott Laboratories
  • Accelerate Diagnostics
  • ADT Biotech
  • Beckman Coulter Diagnostics(Danaher)
  • Becton, Dickinson and Company
  • Binx Health
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid(Danaher)
  • Curetis(OpGen)
  • Day Zero Diagnostics
  • DeepUII Diagnostics
  • DNAe
  • Enzo Biochem
  • Eurofins Scientific
  • Fusion Genomics
  • GeneFluidics
  • Genetic Signatures
  • Great Basin Scientific, Inc
  • Hologic
  • Hutman Diagnostics
  • Inflammatix
  • Linear Diagnostics
  • Lumos Diagnostics
  • MGI
  • Millipore Sigma
  • OpGen
  • Pathogenomix
  • Qiagen
  • QuidelOrtho
  • Revvity
  • Roche Diagnostics
  • Scope Fluidics
  • SeLux Diagnostics
  • Sherlock Biosciences
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific
  • Uniogen
  • Vela Diagnostics
  • Visby Medical

第7章 全球抗生素抗藥性診斷市場

  • 各國全球市場概要
  • 按病原體全球市場- 概要
  • 各技術全球市場- 概要

第8章 全球抗生素抗性診斷市場- 病原體

  • 藥物抗性肺炎球菌-DRSP
  • 藥物抗性曲狀桿菌- 剛果民主共和國
  • 難辨梭狀芽孢桿菌-CD
  • 抗藥性金黃色葡萄球菌(MRSA)
  • 藥物抗性淋菌(DRNG)
  • 藥物抗性沙門菌-DRNTS

第9章 全球抗生素抗性診斷市場- 各技術

  • 微生物學培養
  • 免疫檢測
  • PCR
  • NGS
  • 質譜分析法
  • 迅速檢驗和照護現場

第10章 AMR診斷的未來願景

第11章 附錄

Report Overview:

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. Will these technologies solve the problem before new antibiotics come along? New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile over 30 companies, large and small, working in this area.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

  • 1.1. Antimicrobial Resistance - Strategic Situation Analysis
  • 1.2. Guide for Executives and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. The Threat and Opportunity of Antimicrobial Resistance
  • 2.2. Defining the Opportunity
    • 2.2.1. Revenue Market Size
  • 2.3. Methods and Sources
    • 2.3.1. Methodology
    • 2.3.2. Sources
    • 2.3.3. Authors
  • 2.4. Perspective: Healthcare and the IVD Industry
    • 2.4.1. Global Healthcare Spending
  • 2.5. Spending on Diagnostics
    • 2.5.1. Important Role of Insurance for Diagnostics

3. Overview of a Dynamic Market

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Diagnostic Test Developer
    • 3.1.2. Instrumentation Supplier
    • 3.1.3. Chemical/Reagent Supplier
    • 3.1.4. Pathology Supplier
    • 3.1.5. Independent Clinical Laboratory
    • 3.1.6. Public National/regional Laboratory
    • 3.1.7. Hospital Laboratory
    • 3.1.8. Physicians Office Lab (POLS)
    • 3.1.9. Audit Body
    • 3.1.10. Certification Body
  • 3.2. Understanding Antimicrobial Resistance
    • 3.2.1. What is Antimicrobial Resistance (AMR)
    • 3.2.2. Bacteria and Other Microbes
    • 3.2.3. The History of Antibiotics
    • 3.2.4. The Role of Animal Husbandry
    • 3.2.5. The Implications of Horizontal Transfer
    • 3.2.6. The Threat of AMR
  • 3.3. The Changing Road to New Antibiotics & Technologies
  • 3.4. The Key Role of Diagnostics in AMR

4. The Market Opportunity of AMR

  • 4.1. The Key Large Market Opportunities in AMR
    • 4.1.1. Streptococcus Pneumoniae (DRSP)
    • 4.1.2. Campylobacter (DRC)
    • 4.1.3. Clostridium Difficile (CD)
    • 4.1.4. Staphylococcus aureus (MRSA)
    • 4.1.5. Neisseria gonorrhoeae (DRNG)
    • 4.1.6. Salmonella (DRNTS)
  • 4.2. Diagnostic Technology Development Opportunities
    • 4.2.1. What's Wrong with Microbiology
    • 4.2.2. The Features Battleground of Infectious Disease Diagnostics
    • 4.2.3. Multiplex vs. POC/Rapid
    • 4.2.4. The Miracle of Genetics
    • 4.2.5. From Multiple Pathogens to All Pathogens - The Next Next Generation
    • 4.2.6. Gene Sequence Diagnostics WITHOUT the Sequencing
    • 4.2.7. Markers of Resistance
    • 4.2.8. What Happens to the Microbiology Lab?

5. Antibiotic Resistance Diagnostics Recent Developments

  • 5.1. Antibiotic Resistance Recent Developments
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. DeepUll Raises Euro-50M in Oversubscribed Round
  • 5.3. BioMerieux Gets Clearance for ID/AST System
  • 5.4. New antibiotics could treat 'super bugs'
  • 5.5. Cepheid, Fleming Partner to Address AMR
  • 5.6. Fuse Dx and Prompt Dx Funded for POC Tests
  • 5.7. FDA Approval for Karius
  • 5.8. Presymptom Health Develops Sepsis Test
  • 5.9. Visby Medical to Develop STI and AMR MDx
  • 5.10. Siemens Healthineers to Develop NGS-Based Sepsis Test
  • 5.11. Researchers Developing POC Test for Detecting Risk SNPs
  • 5.12. Curetis, FIND Extend AMR Research
  • 5.13. Delve Bio to Develop Metagenomic Dx
  • 5.14. BioMerieux, Oxford Nanopore Form ID Dx Pact
  • 5.15. DnaNudge, Mylab Forge Dx Partnership
  • 5.16. FDA Clears New bioMerieux Diagnostic System and Panel
  • 5.17. Selux Diagnostics Phenotyping System Gets FDA Approval
  • 5.18. New diagnostics to tackle drug resistant infections
  • 5.19. Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels
  • 5.20. Three companies join forces to tackle antimicrobial resistance (AMR)
  • 5.21. T2 Biosystems Exercises BARDA Option
  • 5.22. OpGen to Ramp up Use of Acuitas AMR Gene Panel
  • 5.23. BD Partners With Pfizer, Wellcome to Study AMR Dx
  • 5.24. Sepsis Test Developers Accelerate Plans
  • 5.25. OpGen Receives FDA Clearance for AMR Panel
  • 5.26. Visby Medical - Rapid Uptake of Handheld PCR Test for STIs
  • 5.27. MicroGenDx, OrthoKey Clinic and OrthoKey Surgery
  • 5.28. BioMerieux Receives CE Mark for Vitek Clinical Microbiology System
  • 5.29. Hologic to Acquire Mobidiag
  • 5.30. Campylobacter strains exchange genes
  • 5.31. Disinfection spreads antimicrobial resistance
  • 5.32. Molzym, Fraunhofer Developing Rapid Sepsis Dx
  • 5.33. Illumina, IDbyDNA Build NGS-Based Respiratory Panel
  • 5.34. Accelerate Diagnostics Expands AMR Testing
  • 5.35. Rapid diagnostics linked to optimal antibiotics
  • 5.36. Visby Medical Wins AMR Diagnostic Competition
  • 5.37. DNAe Technology SARS-CoV-2 Sequences
  • 5.38. Infections with foodborne bacteria becoming harder to treat
  • 5.39. Dust is sharing antibiotic resistance genes

6. Key AMR Diagnostics Companies

  • 6.1. 1928 Diagnostics
  • 6.2. Abbott Laboratories
  • 6.3. Accelerate Diagnostics
  • 6.4. ADT Biotech
  • 6.5. Beckman Coulter Diagnostics (Danaher)
  • 6.6. Becton, Dickinson and Company
  • 6.7. Binx Health
  • 6.8. bioMerieux Diagnostics
  • 6.9. Bio-Rad Laboratories, Inc.
  • 6.10. Cepheid (Danaher)
  • 6.11. Curetis (OpGen)
  • 6.12. Day Zero Diagnostics
  • 6.13. DeepUII Diagnostics
  • 6.14. DNAe
  • 6.15. Enzo Biochem
  • 6.16. Eurofins Scientific
  • 6.17. Fusion Genomics
  • 6.18. GeneFluidics
  • 6.19. Genetic Signatures
  • 6.20. Great Basin Scientific, Inc
  • 6.21. Hologic
  • 6.22. Hutman Diagnostics
  • 6.23. Inflammatix
  • 6.24. Linear Diagnostics
  • 6.25. Lumos Diagnostics
  • 6.26. MGI
  • 6.27. Millipore Sigma
  • 6.28. OpGen
  • 6.29. Pathogenomix
  • 6.30. Qiagen
  • 6.31. QuidelOrtho
  • 6.32. Revvity
  • 6.33. Roche Diagnostics
  • 6.34. Scope Fluidics
  • 6.35. SeLux Diagnostics
  • 6.36. Sherlock Biosciences
  • 6.37. Siemens Healthineers
  • 6.38. Sysmex
  • 6.39. Thermo Fisher Scientific
  • 6.40. Uniogen
  • 6.41. Vela Diagnostics
  • 6.42. Visby Medical

7. The Global Market for Antimicrobial Resistance Diagnostics

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Technology - Overview
    • 7.2.1. Table - Global Market by Pathogen
    • 7.2.2. Chart - Global Market by Pathogen - Base/End Year Comparison
    • 7.2.3. Chart - Global Market by Pathogen - Base Year
    • 7.2.4. Chart - Global Market by Pathogen - End Year
    • 7.2.5. Chart - Global Market by Pathogen - Share by Year
    • 7.2.6. Chart - Global Market by Pathogen - Segment Growth
  • 7.3. Global Market by Technology - Overview
    • 7.3.1. Table - Global Market by Technology
    • 7.3.2. Chart - Global Market by Technology - Base/End Year Comparison
    • 7.3.3. Chart - Global Market by Technology - Base Year
    • 7.3.4. Chart - Global Market by Technology - End Year
    • 7.3.5. Chart - Global Market by Technology - Share by Year
    • 7.3.6. Chart - Global Market by Technology - Segment Growth

8. Global Antibiotic Resistance Diagnostic Markets - By Pathogen

  • 8.1. Drug Resistant Streptococcus Pneumoniae - DRSP
    • 8.1.1. Table DRSP - by Country
    • 8.1.2. Chart - DRSP Growth
  • 8.2. Drug Resistant Campylobacter - DRC
    • 8.2.1. Table DRC - by Country
    • 8.2.2. Chart - DRC Growth
  • 8.3. Clostridium Difficile - CD
    • 8.3.1. Table CD - by Country
    • 8.3.2. Chart - CD Growth
  • 8.4. Methicillin Resistant Staphylococcus Aureus - MRSA
    • 8.4.1. Table MRSA - by Country
    • 8.4.2. Chart - MRSA Growth
  • 8.5. Drug Resistant Neisseria Gonorrhoeae - DRNG
    • 8.5.1. Table DRNG - by Country
    • 8.5.2. Chart - DRNG Growth
  • 8.6. Drug Resistant Salmonella - DRNTS
    • 8.6.1. Table DRNTS - by Country
    • 8.6.2. Chart - DRNTS Growth

9. Global Antibiotic Resistance Diagnostic Markets - by Technology

  • 9.1. Microbiology Culture
    • 9.1.1. Table Culture - by Country
    • 9.1.2. Chart - Culture Growth
  • 9.2. Immunoassay
    • 9.2.1. Table Immunoassay - by Country
    • 9.2.2. Chart - Immunoassay Growth
  • 9.3. PCR
    • 9.3.1. Table PCR - by Country
    • 9.3.2. Chart - PCR Growth
  • 9.4. NGS
    • 9.4.1. Table NGS - by Country
    • 9.4.2. Chart - NGS Growth
  • 9.5. Mass Spectrometry - MS
    • 9.5.1. Table MS - by Country
    • 9.5.2. Chart - MS Growth
  • 9.6. Rapid and Point of Care - Rapid/POC
    • 9.6.1. Table Rapid/POC - by Country
    • 9.6.2. Chart - Rapid/POC Growth

10. Vision of the Future of AMR Diagnostics

11. Appendices

  • 11.1. United States Medicare System: Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1: Market Players by Type
  • Table 2: Known Human Pathogenic Diseases
  • Table 3: The Key Market Opportunities
  • Table 4: Market Potential DRSP Diagnostic
  • Table 5: Market Potential DRC Diagnostic
  • Table 6: Market Potential CD Diagnostic
  • Table 7: Market Potential CD Diagnostic
  • Table 8: Market Potential DRNG Diagnostic
  • Table 9: Market Potential DRNTS Diagnostic
  • Table 10: Key AMR Diagnostics Issues
  • Table 11: Global Market by Region
  • Table 12: Global Market by Pathogen
  • Table 13: Global Market by Technology
  • Table 14: DRSP by Country
  • Table 15: DRC by Country
  • Table 16: CD by Country
  • Table 17: MRSA by Country
  • Table 18: DRNG by Country
  • Table 19: DRNTS by Country
  • Table 20: Culture by Country
  • Table 21: Immunoassay by Country
  • Table 22: PCR by Country
  • Table 23: NGS by Country
  • Table 24: MS by Country
  • Table 25: Rapid/POC by Country
  • Table 26: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Global Healthcare Spending Map
  • Figure 2: The Lab Test Pie
  • Figure 3: The Road to Diagnostics
  • Figure 4: AMR and Antibiotic Introduction
  • Figure 5: The Death Toll of AMR
  • Figure 6: Global Market Share Chart
  • Figure 7: Global Market by Pathogen - Base vs. End Year
  • Figure 8: Global Market by Pathogen Base Year
  • Figure 9: Global Market by Pathogen End Year
  • Figure 10: Pathogen Share by Year
  • Figure 11: Pathogen Segment Growth
  • Figure 12: Technology - Base vs. End Year Segment Shift
  • Figure 13: Technology Market Base Year
  • Figure 14: Technology Market End Year
  • Figure 15: Technology Share by Year
  • Figure 16: Technology Segment Growth
  • Figure 17: DRSP Growth
  • Figure 18: DRC Diagnostics Growth
  • Figure 19: CD Growth
  • Figure 20: MRSA Growth
  • Figure 21: DRNG Growth
  • Figure 22: DRNTS Growth
  • Figure 23: Culture Growth
  • Figure 24: Immunoassay Growth
  • Figure 25: PCR Growth
  • Figure 26: NGS Growth
  • Figure 27: MS Growth
  • Figure 28: Rapid/POC Growth